Orforglipron Demonstrates Superior Blood Sugar Control Compared With Oral Semaglutide

Lilly’s oral glucagon-like peptide-1 (GLP-1), orforglipron, delivered superior blood sugar control and weight loss compared with oral semaglutide in a head-to-head type 2 diabetes (T2D) trial published in The Lancet, signaling a potential shift in the management of metabolic disease.¹

"ACHIEVE-3 gives us the first head-to-head comparison between 2 oral GLP-1 receptor agonist therapies in adults with type 2 diabetes, and the differences were clinically meaningful," Julio Rosenstock, MD, clinical professor of medicine at the University of Texas Southwestern Medical Center, said in the news release.¹ "Orforglipron 12 mg and 36 mg doses outperformed oral semaglutide 7 mg and 14 mg diabetes-related doses on every key end point we measured, including A_1C and weight loss, with improvements appearing as early as 4 weeks and sustained throughout the study."

The phase 3 ACHIEVE-3 trial (NCT06045221), which evaluated 1698 adults with T2D inadequately controlled with metformin, revealed that orforglipron significantly outperformed oral semaglutide across all primary and key secondary end points over a 52-week period. Specifically, the 36 mg dose of orforglipron achieved a 2.2% reduction in A_1C compared to a 1.4% reduction with 14 mg of oral semaglutide.¹

The weight loss results were equally distinct, with participants on the highest dose of orforglipron losing an average of 19.7 pounds, representing a 73.6% greater relative weight loss than those treated with semaglutide.¹

For pharmacists, the most notable clinical differentiator may be the pharmacokinetic profile of orforglipron. Unlike current oral GLP-1 peptide therapies that require strict fasting and water intake protocols, orforglipron is a nonpeptide small molecule that can be administered at any time of day without food or water restrictions. Beyond glycemic control, the drug also demonstrated positive impacts on cardiovascular risk factors, including improvements in nonhigh-density lipoprotein cholesterol, triglycerides, and systolic blood pressure.¹

"The results of ACHIEVE-3 highlight the potential advantages of orforglipron over oral semaglutide for type 2 diabetes: greater A_1C reduction, more weight loss, and the ability to take it without food or water timing restrictions—that's a combination that could matter significantly to people managing their disease day in and day out," Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, said in the news release.¹ "With global submissions underway and FDA action on obesity expected next quarter, we're focused on making this option available as quickly as possible."

The broader ACHIEVE clinical program has further solidified the drug’s standing against other common therapies. In the ACHIEVE-2 (NCT06192108) trial, orforglipron outperformed dapagliflozin, a widely used SGLT-2 inhibitor, and ACHIEVE-5 (NCT06109311) demonstrated its efficacy as an adjunct to titrated basal insulin.²

This versatility is complemented by the ATTAIN-MAINTAIN (NCT06584916) trial results, which showed that orforglipron effectively maintained weight loss in patients who transitioned directly from the highest tolerated doses of injectable therapies like semaglutide (Wegovy) or tirzepatide (Zepbound). This suggests a future role for the medication not only as a primary treatment but also as a convenient oral maintenance option for long-term obesity management.³

From a safety and tolerability perspective, orforglipron remains consistent with the established GLP-1 receptor agonist class, with gastrointestinal issues such as nausea, diarrhea, and vomiting being the most frequently reported adverse events. In ACHIEVE-3, discontinuation rates due to adverse events were slightly higher for orforglipron, ranging from 8.7% to 9.7%, compared with approximately 4.5% to 4.9% for the oral semaglutide cohorts. All study arms utilized a stepwise titration approach to mitigate these effects, with orforglipron participants starting at a 1 mg dose and increasing at 4-week intervals until reaching their maintenance dose.^1,4

As Eli Lilly and Company continues its global regulatory push, having already submitted orforglipron in over 40 countries, the pharmaceutical landscape is bracing for its potential arrival. US regulatory action for the treatment of obesity is anticipated in the second quarter of 2026, with a submission for T2D expected later this year.¹

With its combination of superior efficacy and a simplified dosing regimen free from dietary constraints, orforglipron is positioned by its developers as a potential new standard of care for patients managing the daily complexities of T2D and obesity.^1,2

READ MORE: Diabetes Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet. News release. Eli Lilly. February 26, 2026. Accessed February 26, 2026. https://lilly.mediaroom.com/2026-02-26-Lillys-oral-GLP-1,-orforglipron,-delivered-superior-blood-sugar-control-and-weight-loss-compared-to-oral-semaglutide-in-head-to-head-type-2-diabetes-trial-published-in-The-Lancet?utm_source=LI&utm_medium=organic&utm_campaign=cmh_ooli&utm_id=CMH

2. Gallagher A. Orforglipron Demonstrates Superior Glycemic Control for Type 2 Diabetes. Drug Topics. October 16, 2025. Accessed February 26, 2026. https://www.drugtopics.com/view/orforglipron-demonstrates-superior-glycemic-control-for-type-2-diabetes

3. Gallagher A. Orforglipron Maintains Weight Loss After Discontinuation of Injectable GLP-1. Drug Topics. January 3, 2026. Accessed February 26, 2026. https://www.drugtopics.com/view/orforglipron-maintains-weight-loss-after-discontinuation-of-injectable-glp-1

4. Gallagher A. Orforglipron Shows Significant Weight Loss in New Phase 3 Study. Drug Topics. September 4, 2025. Accessed February 26, 2026. https://www.drugtopics.com/view/orforglipron-shows-significant-weight-loss-in-new-phase-3-study